174 related articles for article (PubMed ID: 34647140)
41. A Review of Predictive Low Glucose Suspend and Its Effectiveness in Preventing Nocturnal Hypoglycemia.
Chen E; King F; Kohn MA; Spanakis EK; Breton M; Klonoff DC
Diabetes Technol Ther; 2019 Oct; 21(10):602-609. PubMed ID: 31335193
[TBL] [Abstract][Full Text] [Related]
42. Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL): A Randomized, Crossover Trial.
McAuley SA; Trawley S; Vogrin S; Ward GM; Fourlanos S; Grills CA; Lee MH; Alipoor AM; O'Neal DN; O'Regan NA; Sundararajan V; Colman PG; MacIsaac RJ
Diabetes Care; 2022 Feb; 45(2):381-390. PubMed ID: 34844995
[TBL] [Abstract][Full Text] [Related]
43. Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study.
Boughton CK; Hartnell S; Thabit H; Mubita WM; Draxlbauer K; Poettler T; Wilinska ME; Hood KK; Mader JK; Narendran P; Leelarathna L; Evans ML; Hovorka R
Lancet Healthy Longev; 2022 Mar; 3(3):e135-e142. PubMed ID: 35359882
[TBL] [Abstract][Full Text] [Related]
44. Rapid Improvement in Time in Range After the Implementation of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes.
Beato-Víbora PI; Gallego-Gamero F; Ambrojo-López A; Gil-Poch E; Martín-Romo I; Arroyo-Díez FJ
Diabetes Technol Ther; 2021 Sep; 23(9):609-615. PubMed ID: 33784187
[No Abstract] [Full Text] [Related]
45. "Let the Algorithm Do the Work": Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients.
Biester T; Kordonouri O; Holder M; Remus K; Kieninger-Baum D; Wadien T; Danne T
Diabetes Technol Ther; 2017 Mar; 19(3):173-182. PubMed ID: 28099035
[TBL] [Abstract][Full Text] [Related]
46. How does a predictive low glucose suspend (PLGS) system tackle pediatric lifespan challenges in diabetes treatment? Real world data analysis.
Gaweł WB; Deja G; Kamińska H; Tabor A; Skała-Zamorowska E; Jarosz-Chobot P
Pediatr Diabetes; 2020 Mar; 21(2):280-287. PubMed ID: 31715059
[TBL] [Abstract][Full Text] [Related]
47. Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study.
Garg S; Brazg RL; Bailey TS; Buckingham BA; Slover RH; Klonoff DC; Shin J; Welsh JB; Kaufman FR
Diabetes Technol Ther; 2012 Mar; 14(3):205-9. PubMed ID: 22316089
[TBL] [Abstract][Full Text] [Related]
48. Switching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control.
Lepore G; Rossini A; Bellante R; Corsi A; Scaranna C; Dodesini AR; Trevisan R
Acta Diabetol; 2022 Oct; 59(10):1309-1315. PubMed ID: 35857108
[TBL] [Abstract][Full Text] [Related]
49. Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial.
Kariyawasam D; Morin C; Casteels K; Le Tallec C; Sfez A; Godot C; Huneker E; Garrec N; Benhamou PY; Polak M; Charpentier G; Franc S; Beltrand J
Lancet Digit Health; 2022 Mar; 4(3):e158-e168. PubMed ID: 35216750
[TBL] [Abstract][Full Text] [Related]
50. Maternal-Fetal Outcomes in 34 Pregnant Women with Type 1 Diabetes in Sensor-Augmented Insulin Pump Therapy.
Gómez AM; Marín Carrillo LF; Arévalo Correa CM; Muñoz Velandia OM; Rondón Sepúlveda MA; Silva Herrera JL; Henao Carrillo DC
Diabetes Technol Ther; 2017 Jul; 19(7):417-422. PubMed ID: 28731823
[TBL] [Abstract][Full Text] [Related]
51. Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial.
Benhamou PY; Franc S; Reznik Y; Thivolet C; Schaepelynck P; Renard E; Guerci B; Chaillous L; Lukas-Croisier C; Jeandidier N; Hanaire H; Borot S; Doron M; Jallon P; Xhaard I; Melki V; Meyer L; Delemer B; Guillouche M; Schoumacker-Ley L; Farret A; Raccah D; Lablanche S; Joubert M; Penfornis A; Charpentier G;
Lancet Digit Health; 2019 May; 1(1):e17-e25. PubMed ID: 33323237
[TBL] [Abstract][Full Text] [Related]
52. Automated Insulin Delivery with SGLT2i Combination Therapy in Type 1 Diabetes.
Garcia-Tirado J; Farhy L; Nass R; Kollar L; Clancy-Oliveri M; Basu R; Kovatchev B; Basu A
Diabetes Technol Ther; 2022 Jul; 24(7):461-470. PubMed ID: 35255229
[No Abstract] [Full Text] [Related]
53. Usage and effectiveness of the low glucose suspend feature of the Medtronic Paradigm Veo insulin pump.
Agrawal P; Welsh JB; Kannard B; Askari S; Yang Q; Kaufman FR
J Diabetes Sci Technol; 2011 Sep; 5(5):1137-41. PubMed ID: 22027306
[TBL] [Abstract][Full Text] [Related]
54. Safety and efficacy of the predictive low glucose management system in the prevention of hypoglycaemia: protocol for randomised controlled home trial to evaluate the Suspend before low function.
Abraham MB; Nicholas JA; Ly TT; Roby HC; Paramalingam N; Fairchild J; King BR; Ambler GR; Cameron F; Davis EA; Jones TW
BMJ Open; 2016 Apr; 6(4):e011589. PubMed ID: 27084290
[TBL] [Abstract][Full Text] [Related]
55. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.
Russell SJ; Hillard MA; Balliro C; Magyar KL; Selagamsetty R; Sinha M; Grennan K; Mondesir D; Ekhlaspour L; Zheng H; Damiano ER; El-Khatib FH
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):233-243. PubMed ID: 26850709
[TBL] [Abstract][Full Text] [Related]
56. Characteristics of Automated Insulin Suspension and Glucose Responses with the Predictive Low-Glucose Management System.
Abraham MB; Smith GJ; Nicholas JA; Fairchild JM; King BR; Ambler GR; Cameron FJ; Davis EA; Jones TW;
Diabetes Technol Ther; 2019 Jan; 21(1):28-34. PubMed ID: 30585769
[TBL] [Abstract][Full Text] [Related]
57. Hybrid Closed-Loop Control Is Safe and Effective for People with Type 1 Diabetes Who Are at Moderate to High Risk for Hypoglycemia.
Anderson SM; Buckingham BA; Breton MD; Robic JL; Barnett CL; Wakeman CA; Oliveri MC; Brown SA; Ly TT; Clinton PK; Hsu LJ; Kingman RS; Norlander LM; Loebner SE; Reuschel-DiVirglio S; Kovatchev BP
Diabetes Technol Ther; 2019 Jun; 21(6):356-363. PubMed ID: 31095423
[No Abstract] [Full Text] [Related]
58. Insulin settings and their association with time in range in patients with type 1 diabetes users of predictive low glucose suspend (PLGS) augmented insulin pumps in Santiago, Chile.
Grassi BA; Caramés B; Plaza-Plaza JC; Onetto MT; Moreno S; Sandoval T; Tapia N; Mena F; Revello A
J Diabetes Complications; 2022 Aug; 36(8):108262. PubMed ID: 35842304
[TBL] [Abstract][Full Text] [Related]
59. Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women With Type 1 Diabetes: A Randomized Controlled Crossover Trial.
Stewart ZA; Wilinska ME; Hartnell S; O'Neil LK; Rayman G; Scott EM; Barnard K; Farrington C; Hovorka R; Murphy HR
Diabetes Care; 2018 Jul; 41(7):1391-1399. PubMed ID: 29535135
[TBL] [Abstract][Full Text] [Related]
60. Patients with highly unstable type 1 diabetes eligible for islet transplantation can be managed with a closed-loop insulin delivery system: A series of N-of-1 randomized controlled trials.
Benhamou PY; Lablanche S; Vambergue A; Doron M; Franc S; Charpentier G
Diabetes Obes Metab; 2021 Jan; 23(1):186-194. PubMed ID: 33001536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
